Amanta Healthcare has successfully commissioned a 10.8 MWp solar power plant at Village Baroda, Taluka Matar, District Kheda, to generate electricity for its captive consumption. The generation of units from the solar power plant commenced on May 30, 2026. This strategic move is expected to reduce the company's operational costs and enhance overall sustainability by utilizing green energy for its manufacturing needs.

The company received all requisite approvals prior to the commencement of operations. The power generated will be utilized entirely for captive consumption, directly supporting Amanta Healthcare's production facilities. This development aligns with the company's objectives to optimize energy expenses and strengthen its environmental footprint.

Project Details

The solar power plant is located in Gujarat and has a capacity of 10.8 MWp. The facility is designed to meet the energy requirements of the company's factory located at Hariyala on National Highway No. 8.

The intimation regarding the commissioning was made to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Amanta Healthcare Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a net profit of INR 15 Cr for the fiscal year 2026, marking a 42% increase from INR 11 Cr in the previous year. Revenue from operations for the year stood at INR 288 Cr, compared to INR 275 Cr in FY25.

For the quarter ended March 31, 2026, the company recorded a net profit of INR 5.5 Cr, while revenue from operations was INR 77 Cr. The board approved the financial results during its meeting held on May 19, 2026.

Financial Performance Summary

The company's total income for FY26 rose to INR 291 Cr from INR 276 Cr in the previous year. Total expenses for the year increased to INR 228 Cr. Profit before tax for the year was INR 21 Cr, up from INR 15 Cr in FY25. EBITDA for the year increased 6.06% YoY to INR 63 Cr, with margins at 22%.

Operational Highlights

Earnings per share (EPS) for the year improved to INR 4.33 from INR 3.71 in the previous year. The company's cash and cash equivalents as of March 31, 2026, were reported at INR 8,101.03 Cr, a significant increase from INR 22.06 Cr in the prior year. This increase was primarily driven by proceeds from the Initial Public Offer (IPO) completed during the year.

The board meeting also reviewed the utilization of IPO proceeds. The company had raised INR 12,600 lakhs through its IPO, with INR 7,353.25 lakhs utilized towards capital expenditure and general corporate purposes as of March 31, 2026. The company reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs).

Business Outlook

During the post-results conference call, management highlighted that the SteriPort platform contributes nearly 42% of revenue from operations. The company is expanding capacity from 6.6 crore bottles per year to roughly 12 crore bottles per year to capture the growing market for two-port systems, which are preferred in therapies like oncology and critical care. The expansion is expected to be operational by June 20, 2026.

Management also noted that the debt-to-equity ratio has improved from 3x to nearly 1x over the last three years. A 10.8 megawatt captive solar power project is under implementation and expected to be commissioned soon, which is anticipated to reduce power costs by approximately INR 75 lakh per month from FY27 onwards. The company expects EBITDA margins to improve to between 24% and 25% going forward, driven by the new SteriPort capacity and cost optimization initiatives.